Clinical Trials Logo

Recurrent Disease clinical trials

View clinical trials related to Recurrent Disease.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03415477 Completed - Recurrent Disease Clinical Trials

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

Deno-ABC
Start date: January 1, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated with pathological fracture. Therefore, denosumab, a new drug that has been successfully used in giant cell tumor of bone but has seldom used in ABC, was used to treat ABC in this trial.

NCT ID: NCT03060096 Completed - Cancer Clinical Trials

Stepped-Care Telehealth for Distress in Cancer Survivors

Telehealth
Start date: July 19, 2018
Phase: N/A
Study type: Interventional

Mental health issues in post-treatment adult cancer survivors are associated with multiple adverse outcomes and may represent a cancer health disparity for rural survivors. The purpose of this study is to test a stepped-care approach tailored to symptom severity based on recent American Society of Clinical Oncology guidelines for reducing emotional distress (anxiety and/or depressive symptoms) and improving secondary outcomes (sleep disturbance, fatigue, fear of recurrence, quality of life) in rural, post-treatment cancer survivors in community oncology settings and to examine intervention costs. The resultant intervention will have great potential for widespread dissemination since it will be manualized, delivered by telephone, and comprised of modules to allow customized treatments for individuals with different cancer types.

NCT ID: NCT02210858 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Start date: May 2000
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1-2 trial studies the side effects and how well tipifarnib works in treating patients with chronic myeloid leukemia, chronic myelomonocytic leukemia, or undifferentiated myeloproliferative disorders. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02204761 Completed - Recurrent Disease Clinical Trials

Proton Beam Re-Irradiation in Thoracic Cancers

Start date: September 9, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies proton beam radiation therapy in treating patients with thoracic cancer that has come back and have received prior radiation therapy. Proton beam radiation therapy uses high energy protons to kill tumor cells and may cause less damage to normal tissue.

NCT ID: NCT01794845 Completed - Clinical trials for Head and Neck Cancer

Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Start date: May 2013
Phase: Phase 2
Study type: Interventional

Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.

NCT ID: NCT01737450 Completed - Neoplasm Metastasis Clinical Trials

Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive

PIK-ORL
Start date: January 2013
Phase: Phase 2
Study type: Interventional

The aim of this study is to determine the activity, to assess the safety and tolerance of BKM120 in adult patients with recurrent or metastatic head and neck cancer progressive under platin and cetuximab-based chemotherapy.

NCT ID: NCT01445080 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Start date: May 30, 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

NCT ID: NCT00383474 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

Start date: August 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of tipifarnib and bortezomib in treating patients with acute leukemia or chronic myelogenous leukemia in blast phase. Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tipifarnib together with bortezomib may kill more cancer cells.

NCT ID: NCT00351975 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Start date: June 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with azacitidine may kill more cancer cells.

NCT ID: NCT00036738 Completed - Clinical trials for Recurrent Adult Acute Lymphoblastic Leukemia

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Start date: July 13, 2001
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia that has responded to previous treatment with imatinib mesylate, dasatinib, or nilotinib. Giving low doses of chemotherapy, such as fludarabine phosphate, and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving mycophenolate mofetil and cyclosporine after the transplant may stop this from happening.